Galectin Therapeutics, Inc. GALTW 深 滬
交易中 12-24 09:53:16 美东时间
0.0425
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0425
- 總市值 0
- 52周最高 0.254
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.024
- 委 比 0.00%
- 總股本 --
- 歷史最高 0.254
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.024
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galectin Advances Belapectin Program, Secures New Insider Financing
Galectin Therapeutics ( ($GALT) ) has issued an update. On December 19, 2025, G...
12-19 21:14
HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11
HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and raises the price target from $6 to $11.
12-17 20:44
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
Galectin Therapeutics ( ($GALT) ) just unveiled an announcement. On December 3,...
12-04 01:28
Galectin Therapeutics GAAP EPS of -$0.13
Galectin Therapeutics press release (GALT): Q3 GAAP EPS of -$0.13. More on Galectin Therapeutics Galectin: With Time Ticking, A Partner Is Needed To Revitalize MASH Program Seeking Alpha’s Quant Ratin...
11-14 21:10
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
The Phase 2 NAVIGATE trial demonstrates that belapectin 2 mg/kg consistently reduces liver stiffness, new variceal development, and improves biomarkers in patients with compensated MASH cirrhosis and portal hypertension, with significant antifibrotic and disease-modifying potential.
11-10 13:00
Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.
09-25 20:24
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock rose 25.5% to $2.66 during Monday's afte...
09-16 05:06
Galectin Therapeutics Highlights Promising Belapectin Results
An update from Galectin Therapeutics ( ($GALT) ) is now available. On September...
09-08 20:21
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $6 price target.
08-14 23:51
Galectin Therapeutics Q2 EPS $(0.12) Beats $(0.16) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is a 40 percent increase over losses of $(0.20) per share from
08-14 20:09
